NeoPancONE Announcement: A Message from Michelle Capobianco
July 22, 2020
[A note from PCNA]
[We are grateful to be sharing the lived experience of Connor and Jen who have documented their personal journey with pancreatic cancer up until Connor’s passing in October 2024, to help other families cope with the challenges of this disease.
This blog article is from a series of content pieces written by these remarkable people.]
For several months the COVID-19 crisishas caused many research projects to slow, but Pancreatic Cancer Canada's research programhasnot been idle. We have taken this time to quietly prepare for our next big project, because even in the midst of a global pandemic, pancreatic cancer patients don't havetime to wait.This month we are seeing the diligent planningof our research community come to lifewith the launch of our latestresearch investment:NeoPancONE.NeoPancONE is a phase II clinical trial that aims to be a curative strategy for resectable pancreatic cancer. This trial takes aneoadjuvant approach to treatment, which means that patients will receive chemotherapy before surgery to shrink their tumour and again after surgery to kill any remaining cancer cells.The impact of this trial will be significant and far reaching. In addition to the neoadjuvant treatment,researchers willmeasurea potential biomarker called GATA6 - a gene identified during our pastresearch investment in the COMPASS trialas one that can helpidentify pancreatic cancer subtypes. By measuringthis potential biomarker, researcherswill help doctors understand which patients will respond best to this treatment,learn more about the aggressiveness of thisdisease and ultimately savemore lives.I invite you to learn more about NeoPancONEandconsider joining us on this incredible journey by making a donation to this critical research. With your help we will raise the rate of pancreatic cancer survival, together.Sincerely,Michelle CapobiancoChief Executive OfficerPancreatic Cancer Canada
